The T1DCRN supports cutting edge clinical research projects at critical stages along the clinical research development pipeline, including early-phase proof-of-concept projects, and large-scale, multicentre clinical trials. We are also promoting collaboration, resource and data sharing to maximise the impact of type 1 diabetes clinical research.
- Closed-loop insulin therapy for people living with type 1 diabetes – Keeping blood glucose levels in a normal range is difficult and places an enormous burden on people living with T1D. This program is evaluating the use of “artificial pancreas” devices in children and adults, and looking at the potential benfits for blood glucose control and quality of life.
- Environmental Determinants of Islet Autoimmunity (ENDIA) – The ENDIA study will follow pregnant women whose unborn baby will have an immediate relative with T1D. The babies and their mothers will be followed throughout pregnancy and the early years of life to look at exposure to potential environmental triggers for T1D. If we can understand exactly what in the environment is harmful or protective, we can develop strategies to prevent T1D.
- FAME 1 Eye Study – Damage to the back of the eye is a common complication of type 1 diabetes, and can lead to blindness. The Fenofibrate and Microvascular Events (FAME) 1 Eye Study is investigating whether fenofibrate, a drug that is used to lower cholesterol and blood fats, can slow or reverse eye damage and other complications in adults with type 1 diabetes.
- Nox inhibition in type 1 diabetic kidney disease – There is an urgent need to develop new treatments to arrest, reverse and prevent the development of kidney complications. This clinical trial is testing a novel antioxidant drug in people with T1D and early kidney disease, to see if it can improve kidney function.
- Reducing blood glucose extremes caused by food and exercise in young people with type 1 diabetes – Everyday activities such as exercise and eating can cause unpredictable fluctuations in blood glucose levels. This program will look at how food and exercise impact blood glucose, so new guidelines for managing food and exercise with T1D can be developed.
- Strategies for drug-free immunosuppression in islet transplantation – A major barrier to widespread use of islet transplantation to cure T1D is immune rejection of the transplanted islets. This program aims to develop novel drug-free strategies for islet transplantation to make this treatment more widely available for people living with T1D.
- Hypoglycaemia Prevention with Predictive Low Glucose Suspension (PLGS) – The PLGS clinical trial is investigating a Predictive Low Glucose Suspend feature on insulin pumps. This study will test a novel algorithm for hypoglycemia prediction under test conditions of excess insulin and moderate intensity exercise, to determine if preemptive insulin suspension is safe and effective.
- Reducing with Metformin Vascular Adverse Lesions in type 1 diabetes (REMOVAL) Australian sub-study – The REMOVAL international study aims to discover whether metformin, a commonly used type 2 diabetes drug, can slow or prevent the early changes which lead to cardiovascular complications in type 1 diabetes. The Australian sub-study looks into the effects of the study treatment on the heart, blood vessels in the eyes and limbs, and on novel blood markers of artheroslerosis progression.
The T1DCRN supports early-phase, proof-of-concept projects to test the feasibility of new ideas.
- Career Development Awards – These awards support the best and brightest innovative thinkers who show outstanding potential to lead and influence the future direction of type 1 diabetes clinical research
- Mentored Clinical Researcher Fellowship – T1DCRN Mentored Clinical Researcher Fellowships enables talented clinician researchers to establish their research career in the field of type 1 diabetes
- Future Research Leaders Program
- The Australasian Diabetes Data Network (ADDN) – ADDN connects real-time diabetes data about thousands of type 1 diabetes patients from specialist centres across on a single platform that allows for a long-term monitoring of diabetes outcomes and participation in clinical research.
- T1DCRN Annual Meetings – Our Annual Meeting is an important opportunity to shape the strategic direction of the T1DCRN, share progress outcomes, form new collaborations.
- T1DCRN Workshop – Our regular workshops enable us to identify priorities and develop strategies for increasing the delivery of type 1 diabetes clinical research in Australia.
- Data-sharing – We are committed to the timely publication and dissemination of all information and materials developed by projects we fund.
Photo: Ethan who has type 1 diabetes, and his mother Kathryn live in Canberra.